Short-term outcome of first episode diagnosis of substance induced psychotic disorder in a large UK cohort by Thompson, Andrew David et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Thompson, Andrew D., Marwaha, Steven, Winsper, Catherine, Everard, L., Jones, P., Fowler, 
D., Amos, T., Freemantle, N., Singh, Swaran P., Marshall, M., Sharma, V. and Birchwood, M. J. 
(2016) Short-term outcome of first episode diagnosis of substance induced psychotic 
disorder : report from the UK National EDEN study. Acta Psychiatrica Scandinavica, 134 (4). 
pp. 321-328. 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/80216  
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  Copyright © 
and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable the 
material made available in WRAP has been checked for eligibility before being made 
available. 
 
Copies of full items can be used for personal research or study, educational, or not-for profit 
purposes without prior permission or charge.  Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
"This is the peer reviewed version of the following Thompson, Andrew D., Marwaha, Steven, 
Winsper, Catherine, Everard, L., Jones, P., Fowler, D., Amos, T., Freemantle, N., Singh, 
Swaran P., Marshall, M., Sharma, V. and Birchwood, M. J. (2016) Short-term outcome of first 
episode diagnosis of substance induced psychotic disorder : report from the UK National 
EDEN study. Acta Psychiatrica Scandinavica, 134 (4). pp. 321-328.  which has been published 
in final form at http://doi.org/10.1111/acps.12623   . This article may be used for non-
commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving." 
 
A note on versions: 
The version presented here may differ from the published version or, version of record, if 
you wish to cite this item you are advised to consult the publisher’s version.  Please see the 
‘permanent WRAP URL’ above for details on accessing the published version and note that 
access may require a subscription. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
 1 
Full Title: Short-term outcome of first episode diagnosis of substance induced 
psychotic disorder in a large UK cohort  
Running title: First episode substance induced psychosis outcome 
Andrew Thompson 1 2, Steven Marwaha 1 3, Catherine Winsper 1, Linda Everard 4, 
Peter B Jones 5, David Fowler 6, Tim Amos 7, Nick Freemantle 8, Swaran P Singh 1 4, 
Max Marshall 9, Vimal Sharma 10 & Max Birchwood 1. 
Affiliations 
1 Division of Mental Health and Wellbeing, Warwick Medical School, University of 
Warwick, UK 
2 North Warwickshire Early Intervention in Psychosis Service, Coventry and 
Warwickshire NHS Partnership Trust, UK 
3 Affective Disorders Service, Tile Hill, Coventry, Coventry and Warwickshire NHS 
Partnership Trust, UK 
4 The Early Intervention in Psychosis Service, Birmingham and Solihull Mental Health 
Foundation Trust, Birmingham, UK 
5 Department of Psychiatry, University of Cambridge and CAMEO, Cambridge and 
Peterborough NHS Foundation Trust, UK 
6 School of Medicine, University of East Anglia, Norwich, and Academic Unit of 
Psychiatry and Department of Psychology, University of Sussex, UK 
7 Academic Unit of Psychiatry, University of Bristol, Bristol, UK 
 2 
8 Department of Primary Care and Population Health, UCL Medical School (Royal 
Free Campus), London, UK  
9 School of Medicine, The University of Manchester, Manchester, UK  
10 Early Intervention Service, Cherry Bank Resource Centre, Cheshire and Wirral 
Partnership NHS Foundation Trust, Ellesmere Port, UK  
 
Address for correspondence: Dr Andrew Thompson, Division of Mental Health and 
Wellbeing, Warwick Medical School, Gibbet Hill, Coventry, CV47AL, UK. Tel: +44 
(0) 2476574387; Fax: +44(0) 02476528375. E-mail 
andrew.d.thompson@warwick.ac.uk 
 
 
  
 3 
Abstract 
Objective 
The incidence and subsequent outcome of first episode Substance Induced Psychotic 
Disorder (SIPD) is unclear. The study aimed to compare the 1-year outcomes of those 
given a SIPD diagnosis by clinicians compared to other psychosis diagnoses in a first 
episode cohort.  
Method 
Data was from a large (n=1027) cohort of First Episode Psychosis (FEP) patients 
admitted to early intervention services in the UK (National Eden). Diagnosis, 
including that of SIPD, was made by treating psychiatrists at baseline using ICD10 
criteria. Details on symptoms, functioning, quality of life, relapse and recovery was 
available at baseline and 12 months.  
Results 
There were 67 cases of SIPD (6.5% of the cohort). At baseline SIPD patients were no 
different to other psychoses on symptoms, functioning and quality of life. At 12 
months there was no difference in SIPD and other psychoses on functioning, quality 
of life or relapse and recovery rates. Levels of psychotic and general symptomatology 
were similar but depressive symptoms were higher in the SIPD group.  
Conclusions 
FEP patients with a diagnosis of SIPD do not appear to have better outcomes that 
those with other primary psychotic diagnoses. The higher levels of depressive 
symptoms may be a specific marker in these patients.  
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Significant outcomes 
 There were no differences in baseline symptoms and functioning levels 
between those with a clinician diagnosis of substance induced psychotic 
disorder (SIPD) and other psychosis diagnoses in a large first episode 
psychosis cohort 
 At 12 months follow-up there were higher levels of depressive symptoms in 
those with SIPD compared to those with other psychosis diagnoses  
 There were no differences in other outcomes between the SIPD and other 
psychosis groups at 12 month follow-up including other symptomatic or 
functional outcomes, rates of relapse and recovery 
Limitations 
 The diagnosis of substance induced psychotic disorder was made by clinicians 
using ICD 10 criteria and not using a specific validated diagnostic tool. The 
diagnosis was only possible if patients disclosed their substance use. 
 The numbers of individuals with SIPD was relatively low reducing the ability 
to identify small differences in outcome 
 Treatment offered to the two psychosis diagnosis groups over the 12 month 
period were not fully characterised 
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Introduction 
Since the early 1990’s the Early Intervention in Psychosis (EIP) movement has led to 
services reconfiguration in the UK and worldwide with specialist Early Intervention 
(EI) teams which aim to treat emerging psychotic disorder and improve functional 
outcomes (1). The early intervention paradigm has assumed a symptom “threshold” 
(in terms of frequency and intensity) approach for what constitutes psychosis (2) that 
encompasses a range of disorders, from schizophrenia spectrum disorders, mood 
disorders with psychosis, and substance induced psychotic disorder (SIPD). However, 
there is debate on whether the treatment of persistent psychotic symptoms assumed to 
be in the context of other primary disorders should be the remit of EI teams (3). 
 
One particular area of debate is whether SIPD should be treated in the same manner 
as other psychoses within these services, or even referred to these services in the first 
place (3). This is predicated on the widespread assumption that outcomes for SIPD 
are different to other psychotic disorders. The current International Classification of 
Diseases ICD10 (4) defines SIPD as “a cluster of psychotic phenomena that occur 
during or following psychoactive substance use but that are not explained on the basis 
of acute intoxication alone and do not form part of a withdrawal state” although the 
category of residual and late-onset psychotic disorder would also be considered here, 
though often presenting at a later age (ICD 10). The prevalence of SIPD has been 
estimated to be 1.9/100,000 person years, which is around 5% of all case of psychosis 
(5). However, as lifetime prevalence of substance use in first episode patients is high, 
as is the levels of substance use at presentation to services (6), diagnostic difficulties 
are common. Studies have reported the diagnosis of SIPD is relatively unstable and 
there is a considerable “progression” to more schizophreniform diagnoses (7-9). A 
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follow-up sample with a primary psychotic disorder plus substance use and those with 
SIPD revealed that they also receive different treatment approaches such as 
differential prescribing of antipsychotic medication (10). Other studies have reported 
that SIPD patients are less likely to be hospitalized, less likely to be started on 
antipsychotics and referred to psychiatry that those with primary psychotic disorder 
(11). Clinically this is usually justified on the basis of an assumption that SIPD has a 
good short-term prognosis, will be short lived and self-limiting with ultimate 
resolution being provided by abstinence from the substance. Good quality evidence 
for these widespread clinical assumptions is however lacking (12) and the current 
evidence is conflicting with some studies suggesting there is a good outcome (10) and 
other reporting high rates of psychotic relapse in SIPD (8).  
 
Given these findings of diagnostic instability and uncertain outcomes there is a lack of 
clarity on the most suitable care pathway that should be instituted for these patients 
presenting with a first episode. In a critical review of SIPD, the authors identified 
only 18 articles specifically focusing on delineating the clinical characteristics or 
outcomes and only 1 that reported 1 year follow up data (12). There have been no 
studies to our knowledge that have investigated both symptomatic and functional 
outcomes in incident cases of SIPD compared to other diagnostic groups. This 
information would have considerable implications for treatment and follow-up of 
these patients. For example, should the outcomes be substantially better, there may be 
an argument for shorter or less intensive treatment pathways. 
 
Aims of the study 
 8 
The study aimed to investigate the 12-month outcome of first episode psychosis 
patients in a large UK first episode psychosis cohort who were diagnosed with a SIPD 
compared to other psychotic disorders. There were two hypotheses: 1) functional 
outcomes in SIPD would be similar to other psychotic disorders 2) symptomatic 
outcomes would be better in the SIPD group than for other psychotic disorders and 
they would experience fewer relapses. 
 
Methods and materials 
Sample 
The data was taken from the national EDEN database (13) of 1027 first episode 
psychosis cases admitted to EI services between August 2005 to April 2009 from five 
geographical sites across England: Birmingham, Cornwall, Cambridge, Norwich and 
Lancashire (13). EDEN was a study of outcomes in UK Early Intervention Services. 
The UK Department of Health guidance for inclusion into these services is broad and 
requires only that patients are ‘aged between 14 and 35 with a first presentation of 
psychotic symptoms’ (14). Data was recorded throughout the treatment with the 
service up to 12 months. For further details of the sample see Birchwood et al (13). 
The treatment pathway in EI services is determined by the UK National Institute for 
Health and Care Excellent guideline for Schizophrenia and Psychosis (15) and the 
national IRIS Early Psychosis guidelines (16). The standard length of treatment for 
any patient accepted into an EI service in the UK is 3 years. Team structure for EIS 
teams in the UK has previously been recommended by the Department of Health (14).  
Ethical approval for the study was given by Suffolk Local Research Ethics 
Committee, UK. 
 9 
 
Diagnostic groups 
Research assistants recorded ICD 10 diagnoses made by the treating consultant at 
entry to the service from the clinical files.  The OPerational CRITeria (OPCRIT) 
diagnostic system was also used in the cohort but OPCRIT does not give a diagnosis 
of SIPD as one of the outputs (17). There was a number of diagnoses made including 
substance induced psychosis, schizophrenia, schizoaffective disorder, bipolar 
disorder, delusional disorder and unspecified psychosis. Unspecified psychosis was 
the largest diagnostic group, likely due to these clinical diagnoses being made at first 
contact with services when duration of symptoms may be less clear, symptoms fluid 
and a generic diagnosis of “first episode psychosis” (or unspecified psychosis) 
common practice in UK early psychosis services. Those with a diagnosis of SIPD 
were compared to the overall group of other psychosis diagnoses. 
 
Outcome measures  
A number of symptom and functional outcomes were available at 12-month follow-up 
as well as at baseline in the cohort.  
i) Symptoms 
The following symptom scales were available at baseline and 12 months: Positive and 
Negative Syndrome Scale (PANSS), yielding total, general, negative and positive 
symptoms scores (18)); The Young Mania Rating scale (YMRS) (19); The Calgary 
Depression Scale (20); The Global Assessment of Functioning (GAF) scale (21) 
(symptoms indicated by GAF total, GAF symptoms). 
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ii) Functioning and quality of life measures 
The following functioning and quality of life measures were used that were collected 
at baseline and 12 months: The Global Assessment of Functioning (GAF) scale (21) 
(functioning indicated by GAF total, GAF disability); EuroQual 5 Dimensions 
Questionnaire (EQ-5D) (22) (using the overall score and the health thermometer 
score); Time use survey (23). 
iii) Relapse and recovery 
Using standard international definitions of relapse and recovery from the Bebbington 
et al method (24) this was summated at 12 months to give rates for both of these 
outcomes at this time point. 
 
Analyses 
The baseline characteristics of those with a diagnosis of SIPD with the group with 
other psychosis diagnoses was compared. Differences were compared statistically 
using analysis of variance and chi-squared tests. A regression model was used to 
investigate outcome by diagnostic group, with the individual outcome of interest at 12 
months as the independent variable and diagnostic group as the dependent variable. 
Covariates in an adjusted model included age, gender, ethnicity, Duration of 
Untreated Psychosis (DUP) and baseline outcome scores. Analyses were performed 
using SPSS version 22.  
 
Results 
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Of the 1027 cases in the National Eden database, there were 954 (92.9%) individuals 
with a recorded clinical diagnosis at baseline (entry to the service). Of this sample of 
954 individuals, 685 (66.7%) had a diagnosis of unspecified psychosis, 136 (13.2%) 
schizophrenia, 50 (4.9%) bipolar disorder, 16 (1.6%) schizoaffective disorder and 67 
(6.5%) SIPD. The patients used a multitude of substances and the rate of previous 
illicit substance use was high in the total sample (65.2%). However, when 
investigating the primary substance used in both the SIPD and other psychosis groups 
this was predominantly cannabis (93.7% in the other psychosis group and 93.8% in 
the SIPD group). The SIPD group were far more likely to use more than one 
substance, for example the percentage of the SIPD group reporting use of a second 
substance was 75.6% compared to 37.8% in the other psychoses group. However, it 
was not specified which if any of the substances used was implicated as the primary 
cause of the SIPD.  
 
Baseline characteristic of the sample 
The baseline characteristics of the sample are presented in Table 1. There were no 
significant differences in demographic characteristics between SIPD and the other 
psychoses group, (see Table 1). There were there also no significant differences 
between the two diagnostic groups at baseline on symptoms, functioning and quality 
of life (see Table 2) with the only (expected) difference being the lifetime use of 
substances. 
    
Insert Table 1 around here 
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   Insert Table 2 around here 
 
Differences at 12 months outcome 
At 12 months post diagnosis there were few differences between the SIPD group and 
the other psychosis group. Scores on functioning, quality of life and rates of relapse 
and recovery were not different between the two groups. This was the case for both 
the unadjusted analyses and the analysis adjusted for age, gender, ethnicity, DUP and 
baseline score. The only significant difference on symptoms was that the SIPD group 
scored higher on the Calgary Depression Scale (both unadjusted and adjusted for age, 
gender, ethnicity, DUP and baseline Calgary score) (see Table 3). Rates of substance 
use in the 3 months prior to follow-up were still significantly higher in the SIPD 
group than the other psychosis group 55.1% in the SIPD group and 25.2% in the other 
psychosis group, p<0.001). 
 
   Insert Table 3 around here 
 
Discussion 
Summary of results 
In this study the outcome of the clinician diagnosis of SIPD compared to other 
psychotic diagnoses was compared using data from a large first episode psychosis 
cohort. The study found that functional outcomes for individuals with SIPD were not 
different to those with other primary psychotic disorders. This supported the first 
hypothesis which was functional outcomes in SIPD would be similar to other 
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psychotic disorders. The functional and quality of life outcomes were improved for all 
disorders but remain relatively low for SIPD despite 12 months of treatment in an 
early psychosis service. However, contrary to the second hypothesis, levels of relapse 
and recovery were similar in the SIPD and other psychosis group. The only difference 
on symptomatic outcome was that the SIPD group had higher levels of depression at 
12 months.  
 
Comparison to other research 
There have been few other research studies comparing the outcome of first episode 
SIPD to other psychotic disorders. In a critical review of SIPD, the authors identified 
only 18 articles specifically focusing on delineating the clinical characteristics or 
outcomes and only 1 that reported 1 year follow up data (12). A report from the US 
highlighted differences between drug induced psychosis and those with primary 
psychosis and concurrent substance use at baseline (25). In terms of symptoms they 
reported that the drug induced psychosis group had more visual hallucinations but that 
the primary psychosis group had higher scores in the PANNS negative, positive and 
general scales as well as lower insight scores. Remission rates were also higher in the 
SIPD group (26). This was not the case in this cohort. There are some differences in 
the samples, which might explain these differences. Although the above sample was 
first episode sample, patients were recruited from emergency departments in the US 
whereas our sample was from all patients accepted into UK first episode psychosis 
services, which is the modal pathway for first episode treatment in the UK. It may 
also be that the treatments provided to these diagnostic groups are different in the US 
and the UK.  
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Others have suggested that there may be distinct psychopathological differences 
between SIPD and primary psychosis, including levels of affective symptoms (27) 
and this might help to distinguish the diagnosis of SIPD from primary psychotic 
disorders with substance use. Related to this is the suggestion of high rates of 
progression to an affective disorder in this group as well as a psychotic disorder (28). 
This study also found that affective symptoms, especially depressive symptoms at 
follow-up, were different in the two groups. At present we are unsure if this reflects 
different treatment pathways, worse adherence to treatment in this group, the 
consequences of continued significant substance use, or an affective marker in these 
patients but this would warrant further study. Others have found different factors that 
are able to predict the diagnosis of SIPD versus a primary psychotic disorder 
including family history of psychosis, trauma history and current cannabis 
dependence (29) and distinct differences in symptom profile at baseline (30). There 
may also be some differences due to the type of substance inducing the psychotic 
disorder (31). There is also work investigating whether there are neurobiological 
differences to distinguish these two diagnostic groups (32). We found no differences 
at baseline other than prior history of substance use to distinguish these groups at 
baseline in our cohort. 
 
Strengths and limitations 
The numbers in the overall EDEN database are large and it represents the largest 
cohort of first episode psychosis patients receiving treatment available currently. 
However, the numbers of individuals with SIPD are still relatively low (n=67). Given 
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the relatively small numbers in the SIPD group estimation was conducted with 
relatively low precision, especially with regard to the difference in symptomatic 
outcome and relapse. However, there were multiple symptom measures available, the 
confidence intervals for most of the symptom measures in the SIPD group were 
relatively narrow and the finding of increased levels of depression in the SIPD was 
supported by extant literature. There were some missing data on both symptoms and 
functioning for both groups but this was relatively modest. Hence a missing data 
analysis was not performed. The diagnosis of SIPD was made by the consultant 
psychiatrist in the EI service using ICD 10 criteria and recorded by the researcher but 
the diagnosis not made using a structured interview such as the SCAN (33). Therefore 
our results essentially reflect the outcome of what psychiatrists believe represents a 
diagnosis of SIPD at entry to an EI service. Whilst this might indicate a reduced 
reliability of diagnosis in research terms, our findings on the other hand do strongly 
represent routine clinical practice and have considerable face validity and clinical 
relevance. OPCRIT (15) diagnoses were available for this cohort, but OPCRIT does 
not give a diagnosis of SIPD as an output. The diagnosis of SIPD has been shown to 
have reasonable validity, although with some caveats (12), and does encompass 
psychosis induced by a variety of psychoactive substances, with some possible 
differences in presentation between these (34). The rate of SIPD diagnosis in the 
cohort as a whole (6.5%) also does match well with the published incidence rates for 
all psychotic disorders versus substance induced psychotic disorders (5). However, 
further research is needed in FEP samples using validated and reliable diagnostic 
tools to substantiate these findings. In this sample we do have a high number of non-
specific diagnoses (unspecified psychosis) made by clinicians likely due to the 
widespread practice of giving a non specific psychosis diagnosis on entry to EIS but 
 16 
some clinicians have made the decision on the diagnosis of SIPD early in the course. 
We are not clear whether this reflects a degree of certainty from the clinician or a 
tendency to attribute an aetiological (and possibly less stigmatizing) cause for the 
presentation. We were unable to compare the specific treatments that the diagnostic 
groups received. The treatment offered by EI services in the UK is a broadly 
consistent 3-year program, following NICE guidance (15), although specifically 
tailored by the individual patient formulation and to some extent the diagnosis. Lastly, 
we are aware that we have investigated the relatively short-term outcome of these 
patients and there is a need to consider the long-term outcome further. 
 
 
Clinical implications 
The results have implications for both those who refer to early psychosis services 
such as emergency departments, acute services and other community psychiatric 
teams and for the treatment of patients with SIPD within these services. EI services 
have debated whether SIPD should be treated within their teams and at times these 
patients anecdotally have not been referred to EI services (3). The results from this 
study would suggest that outcomes of patients given this diagnosis by psychiatrists 
are not significantly more favourable, in fact they have poorer affective outcomes. In 
this respect, they are in need of a service based on both symptomatic and functional 
outcomes. As such this may argue for a more assertive treatment approach for this 
group and challenge clinical strategy based on the view that long-term follow-up is 
not required. The incidence of substance induced psychosis reported in a recent meta-
analysis is 1.9/100,000 person years is not insignificant (5). The literature on the rates 
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of development schizophreniform disorder in those with an initial diagnosis of 
substance induced psychosis would suggest that EI services are best placed to provide 
this service, especially if the teams have specific training in treatment of dual 
diagnosis. Having said this, the predictors of poor outcome in SIPD are relatively 
understudied and knowledge of these predictors would help to “stream” treatment 
approaches within services. Our work suggests that psychosis linked to substance 
misuse has poor outcomes, whether the substance misuse is a seen as ‘comorbidity’, 
or a risk factor, or deemed to have triggered the psychosis. The treatment of 
depressive symptoms needs further emphasis, especially as we know that substance 
use is a risk factor for suicide in first episode patients (35). 
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